ATN cerebrospinal fluid biomarkers in dementia with Lewy bodies: Initial results from the United States Dementia with Lewy Bodies Consortium

• DOI: 10.1002/alz.13398
• Publication Date: 2023-09-23T17:19:12Z
• Authors: Lavanya Jain; Maria Khrestian; Shane Formica; Elizabeth D. Tuason; Jagan A. Pillai; Stephen Rao; Odinachi Oguh; Carol F. Lippa; Oscar L. Lopez; Sarah B. Berman; Debby W. Tsuang; Cyrus P. Zabetian; David J. Irwin; Douglas R. Galasko; Irene Litvan; Karen S. Marder; Lawrence S. Honig; Jori E. Fleisher; James E. Galvin; Andrea C. Bozoki; Angela S. Taylor; Marwan N. Sabbagh; James B. Leverenz; Lynn M. Bekris
• Keywords: Neuropathology

Abstract INTRODUCTION The National Institute on Aging – Alzheimer's Association (NIA‐AA) ATN research framework proposes to use biomarkers for amyloid (A), tau (T), and neurodegeneration (N) stage individuals with AD pathological features track changes longitudinally. overall aim was utilize this characterize pre‐mortem status longitudinally in a clinically diagnosed cohort of dementia Lewy bodies (DLB) correlate it the post mortem diagnosis. METHODS subtyped by cerebrospinal fluid (CSF) category. A subcohort had longitudinal data, subgroup neuropathologically evaluated. RESULTS We observed significant difference Aβ 42/40 after 12 months A+T− group. Post neuropathologic analyses indicated that most p‐Tau 181 positive (T+) cases also high Braak stage. DISCUSSION This suggests DLB patients who are A+ but T− may need be monitored determine whether they remain or ever progress T positivity. Highlights Some A+T‐ subjects transition from negative 12‐months. Clinically LBP‐AD (A+T+) maintain their Monitoring sub‐type necessary.